Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 86 The United Laboratories International Holdings Limited Annual Report 2022 5. REVENUE AND SEGMENT INFORMATION (Continued) (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2022 Intermediate Bulk Finished products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 800,893 – – 800,893 – 800,893 – Antibiotics products – 5,168,835 3,062,977 8,231,812 – 8,231,812 – Insulin Products – – 1,095,957 1,095,957 – 1,095,957 – Others 798,312 5,891 401,397 1,205,600 – 1,205,600 Revenue from contracts with customers 1,599,205 5,174,726 4,560,331 11,334,262 – 11,334,262 Inter-segment sales 2,718,504 870,178 – 3,588,682 (3,588,682) – Segment revenue 4,317,709 6,044,904 4,560,331 14,922,944 (3,588,682) 11,334,262